Actinium Pharmaceuticals (ATNM) Change in Accured Expenses (2010 - 2026)

Actinium Pharmaceuticals (ATNM) has reported Change in Accured Expenses for 17 consecutive years, with -$661000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 36.87% year-over-year to -$661000.0; the TTM figure through Mar 2026 stood at $40000.0 (up 104.02% YoY), while the FY2025 annual figure was -$346000.0, up 10.59% from the prior year.
• Change in Accured Expenses retreated to -$661000.0 in Q1 2026 per ATNM's latest filing, from $997000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.3 million in Q4 2022 and bottomed at -$2.8 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $60235.3 across 5 years, with a median of -$196000.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 505.76% — and 2024, when it sank 306.15%.
• Actinium Pharmaceuticals' Change in Accured Expenses stood at $2.3 million in 2022, then tumbled by 108.67% to -$196000.0 in 2023, then surged by 289.29% to $371000.0 in 2024, then soared by 168.73% to $997000.0 in 2025, then slumped by 166.3% to -$661000.0 in 2026.
• Business Quant data shows ATNM's Change in Accured Expenses at -$661000.0 in Q1 2026, $997000.0 in Q4 2025, and -$1.5 million in Q3 2025.